1.69  0 (0%)		09-18 15:28
Open: 1.69 High: 1.69 Volume: 190		Pre. Close: 1.69 Low: 1.69 Market Cap: 3(M)

Short term
Mid term
Targets	6-month :	2.39	1-year :	2.8
Resists	First :	2.05	Second :	2.4
Pivot price	1.93
Supports	First :	1.49	Second :	1.23
MAs	MA(5) :	1.79	MA(20) :	1.96
	MA(100) :	2.3	MA(250) :	1.73
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	0	D(3) :	4.6
RSI	RSI(14): 39.4
52-week	High :	3.77	Low :	0.15

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ KRBP ] has closed above bottom band by 1.6%. Bollinger Bands are 41.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.69 - 1.7	1.7 - 1.71
Low:	1.67 - 1.68	1.68 - 1.69
Close:	1.67 - 1.69	1.69 - 1.71

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Wed, 18 Sep 2024
Kiromic BioPharma (NASDAQ:KRBP) Shares Down 6.1% - Defense World

Wed, 18 Sep 2024
Analyzing Ikena Oncology (NASDAQ:IKNA) & Kiromic BioPharma (NASDAQ:KRBP) - Defense World

Wed, 14 Aug 2024
Kiromic BioPharma’s Deltacel Receives FDA Fast Track Designation - StockTitan

Fri, 05 Jan 2024
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial - Business Wire

Wed, 13 Sep 2023
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14 - Business Wire

Thu, 08 Sep 2022
KRBP CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm's Attorneys, Securities Class Action Pending - AccessWire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	1 (M)
Held by Insiders	27 (%)
Held by Institutions	0 (%)
Shares Short	46 (K)
Shares Short P.Month	62 (K)

EPS	-6.29
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-3.35
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-107 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-12.98
Qtrly Earnings Growth	0 %
Operating Cash Flow	-25 (M)
Levered Free Cash Flow	-20 (M)

PE Ratio	-0.27
PEG Ratio	0
Price to Book value	-0.51
Price to Sales	0
Price to Cash Flow	-0.11

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.